Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fate Therapeutics
(NQ:
FATE
)
3.540
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fate Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
Recap: Fate Therapeutics Q4 Earnings
February 26, 2024
Via
Benzinga
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 26, 2024
February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
Via
Benzinga
A Preview Of Fate Therapeutics's Earnings
February 23, 2024
Via
Benzinga
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Analyst Ratings for Fate Therapeutics
November 09, 2023
Via
Benzinga
Recap: Fate Therapeutics Q3 Earnings
November 08, 2023
Via
Benzinga
Fate Therapeutics Inc. (NASDAQ: FATE) Near the Top of Equities by Percentage Gain on 9/18
September 18, 2023
Via
Investor Brand Network
Analyst Ratings for Fate Therapeutics
September 07, 2023
Via
Benzinga
Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock
January 29, 2024
Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%.
Via
InvestorPlace
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
January 08, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 03, 2024
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
The Latest Analyst Ratings for Fate Therapeutics
August 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 12, 2023
Via
Benzinga
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 08, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
November 03, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
October 25, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at Upcoming September Investor Conferences
August 31, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
August 27, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
August 08, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
August 01, 2023
On Tuesday, 46 stocks hit new 52-week lows.
Via
Benzinga
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results
July 28, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
June 30, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
June 21, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Why Shares of Fate Therapeutics Soared This Week
June 16, 2023
The company's shares bounced back after a stock sale last week.
Via
The Motley Fool
Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
June 08, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
FATE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fate Therapeutics, Inc. - FATE
June 05, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Fate Therapeutics to Present at Upcoming June Investor Conferences
May 31, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.